{
    "data": [
        {
            "id": "4314400",
            "type": "article",
            "attributes": {
                "publishOn": "2019-12-29T07:44:15-05:00",
                "isLockedPro": false,
                "commentCount": 14,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Incyte Corporation: Wait And Watch",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "41431",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "250705",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1092",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4314400-incyte-corporation-wait-and-watch"
            }
        },
        {
            "id": "4310474",
            "type": "article",
            "attributes": {
                "publishOn": "2019-12-04T11:12:56-05:00",
                "isLockedPro": false,
                "commentCount": 2,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Incyte's NDA For Pemigatinib Drug Accepted, But It Is Not A One Hit Wonder",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "58061",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "245202",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1092",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4310474-incytes-nda-for-pemigatinib-drug-accepted-is-not-one-hit-wonder"
            }
        },
        {
            "id": "4306993",
            "type": "article",
            "attributes": {
                "publishOn": "2019-11-15T10:20:29-05:00",
                "isLockedPro": false,
                "commentCount": 4,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Incyte: A Buy On Revenue, EPS Growth And Strong Pipeline",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "24757",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "81289",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1092",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4306993-incyte-buy-on-revenue-eps-growth-and-strong-pipeline"
            }
        },
        {
            "id": "4302109",
            "type": "article",
            "attributes": {
                "publishOn": "2019-11-04T06:21:37-05:00",
                "isLockedPro": false,
                "commentCount": 26,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Incyte: An Undervalued Biotech With Catalysts",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "43041",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "78650",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1092",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4302109-incyte-undervalued-biotech-catalysts"
            }
        },
        {
            "id": "4294204",
            "type": "article",
            "attributes": {
                "publishOn": "2019-09-30T13:52:03-04:00",
                "isLockedPro": false,
                "commentCount": 7,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Incyte Corp.: Maybe The Next Netflix",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "101822",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "70440",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1092",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4294204-incyte-corp-maybe-next-netflix"
            }
        },
        {
            "id": "4282489",
            "type": "article",
            "attributes": {
                "publishOn": "2019-08-07T06:23:56-04:00",
                "isLockedPro": false,
                "commentCount": 4,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Buy Incyte On Attractive Risk/Reward",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "105265",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "57990",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1092",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4282489-buy-incyte-on-attractive-risk-reward"
            }
        },
        {
            "id": "4253282",
            "type": "article",
            "attributes": {
                "publishOn": "2019-04-08T10:26:50-04:00",
                "isLockedPro": false,
                "commentCount": 11,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Regardless Of The Imminent PTAB Ruling, Concert Still Needs To Deal With Incyte's '335 Patent",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "102730",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "28812",
                            "type": "sentiment"
                        },
                        {
                            "id": "28813",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1092",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4253282-regardless-of-imminent-ptab-ruling-concert-still-needs-to-deal-incytes-335-patent"
            }
        },
        {
            "id": "4252836",
            "type": "article",
            "attributes": {
                "publishOn": "2019-04-04T14:43:44-04:00",
                "isLockedPro": false,
                "commentCount": 5,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Incyte Value Will Remain Highly Dependent On Jakafi Sales In 2019",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "24757",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "28254",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1092",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4252836-incyte-value-will-remain-highly-dependent-on-jakafi-sales-in-2019"
            }
        }
    ]
}